Shorter radiation blasts prostate tumors in early trial

NCT ID NCT03269422

Completed Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This early-phase study tests a new, ultra-short course of radiation therapy for men with intermediate-risk prostate cancer. The treatment uses MRI guidance to precisely target the prostate and the main tumor inside it. The goal is to see if this approach is safe and practical, with a focus on limiting side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERMEDIATE RISK PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Memorial Sloan Kettering Basking Ridge (Consent only and follow up)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Commack

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Consent and follow up)

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester

East White Plains, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.